RxDoctor Payments Data

Katherine Rogers, MD

Urology · Rome, GANPI 1265956916

Payments from drug & device makers

$4,261in general payments, 2019–2025

Across 76 payments — averaging $56.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$625
  • Coloplast$428
  • Palette Life Sciences, Inc.$366
  • Teleflex LLC$359
  • Axonics, Inc.$321
  • plus $638 from 13 others

What the payments were for

  • Food & beverage$4,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,261 in reported general payments places this provider in the 45th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$149,497
Medicare patients
497
Services billed
5,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron127$69,207
MyrbetriqMirabegron25$16,264
Estradiol135$9,816
Tamsulosin Hcl183$2,267
Tolterodine Tartrate ErTolterodine Tartrate21$1,157
Potassium Citrate ErPotassium Citrate12$969
NitrofurantoinNitrofurantoin Macrocrystal68$883
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$791
Oxybutynin Chloride ErOxybutynin Chloride27$299
CefuroximeCefuroxime Axetil16$263
Ciprofloxacin Hcl56$257
Minocycline Hcl30$255
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$254
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$224
Cephalexin50$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$37$69,207127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 369 urology providers in Georgia.

Other urology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →